| Theme | Characteristic Problems in Managing Female Dialysis Patients | |
|---|---|---|
| Title | Hemodialysis in systemic lupus erythematosus patients | |
| Publish Date | 2003/07 | |
| Author | Wako Yumura | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Keiko Uchida | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Shinya Suganuma | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Takahito Moriyama | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Masayo Naito | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Minako Koike | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Takashi Takei | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Kousaku Nitta | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| Author | Hiroshi Nihei | Department of Medicine, Kidney Center, Tokyo Women's Medical University |
| [ Summary ] | Systemic lupus erythematosus (SLE) is a collagen disease, which occurs more often in women. Renal failure resulting from lupus nephritis leads to approximately 300 patients requiring hemodialysis every year, accounting for roughly 1% all of new patients who begin hemodialysis. SLE had generally been thought to be eliminated at the beginning of hemodialysis, but it has recently been shown to recur often during treatment. SLE patients need different kinds of care at the start of and during hemodialysis treatment, compared to those who start it owing to primary renal diseases, such as chronic nephritis. At the start of hemodialysis, infectious complications and blood access troubles commonly occur. During hemodialysis, evidence of active SLE (immunological abnormalities, fever, arthralgia, alopecia, erythema, etc.) is often noted. Physicians are required to be familiar with these facts and give appropriate treatment and care to SLE patients receiving hemodialysis. In these patients, it is most important to effectively use immunosuppressive agents (mainly steroids) for SLE, and anticoagulation or antiplatelet therapy in order to maintain adequate blood flow. In the long-term, close attention should be paid to cardiovascular complications and infection as in other hemodialysis patients. |
|